PMID- 30095394
OWN - NLM
STAT- MEDLINE
DCOM- 20190211
LR  - 20190215
IS  - 1539-6304 (Electronic)
IS  - 1088-5412 (Linking)
VI  - 39
IP  - 4
DP  - 2018 Jul 1
TI  - Efficacy and safety of omalizumab in pediatric patients with high immunoglobulin 
      E levels: A case series.
PG  - 289-291
LID - 10.2500/aap.2018.39.4146 [doi]
AB  - BACKGROUND: The efficacy and safety of omalizumab has been demonstrated in 
      children as young as 6 years of age. Omalizumab is currently approved for a range 
      of immunoglobulin E (IgE) levels that differ by age. In patients with IgE levels 
      higher than the indicated therapeutic window, only a few studies have 
      demonstrated the efficacy and safety of its use. Specifically, no reported 
      studies exist to describe the use of omalizumab in pediatric patients with asthma 
      ages <12 years and with high IgE levels. OBJECTIVE: We reported a series of 
      pediatric patients who were initiated on omalizumab despite an IgE level higher 
      than the age-indicated therapeutic windows and aimed to describe whether 
      omalizumab was safe and improved asthma outcomes. METHODS: Patients who initiated 
      omalizumab in our pediatric allergy clinic between January 2008 and December 
      2015, with serum IgE levels higher than the age-indicated therapeutic ranges were 
      included. Patient charts were reviewed to determine the number of asthma-related 
      events in the 12 months before and after initiation of omalizumab and the Asthma 
      Control Test scores at the time of initiation and at 12 months of therapy. 
      RESULTS: Eleven patients were identified with pretreatment IgE levels higher than 
      the age-approved thresholds. Five patients were ages <12 years, and six patients 
      were ages >12 years. For all but one patient, the maximum recommended dose of 375 
      mg every 2 weeks was effective in reducing the need for corticosteroids, 
      emergency department visits, or hospitalizations in the year after initiation of 
      therapy. During the period of therapy, there were no reports of severe reactions. 
      CONCLUSION: Despite a small study group, our results indicated that omalizumab 
      may be safely used in pediatric patients with IgE levels higher than the 
      indicated therapeutic windows.
FAU - Wang, Kathleen Y
AU  - Wang KY
AD  - From the Division of Allergy and Immunology, The Children's Hospital of 
      Philadelphia, Philadelphia, Pennsylvania.
FAU - Sindher, Sayantani B
AU  - Sindher SB
AD  - Stanford Association for Food Allergy Research, Stanford University, Mountain 
      View, California.
FAU - Stinson, Rosemary
AU  - Stinson R
AD  - From the Division of Allergy and Immunology, The Children's Hospital of 
      Philadelphia, Philadelphia, Pennsylvania.
FAU - DaVeiga, Sigrid Payne
AU  - DaVeiga SP
AD  - From the Division of Allergy and Immunology, The Children's Hospital of 
      Philadelphia, Philadelphia, Pennsylvania.
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Allergy Asthma Proc
JT  - Allergy and asthma proceedings
JID - 9603640
RN  - 2P471X1Z11 (Omalizumab)
RN  - 37341-29-0 (Immunoglobulin E)
SB  - IM
MH  - Adolescent
MH  - Child
MH  - Female
MH  - Humans
MH  - Hypergammaglobulinemia/*blood/diagnosis/*drug therapy
MH  - Immunoglobulin E/*blood
MH  - Male
MH  - Omalizumab/administration & dosage/adverse effects/*therapeutic use
MH  - Treatment Outcome
EDAT- 2018/08/11 06:00
MHDA- 2019/02/12 06:00
CRDT- 2018/08/11 06:00
PHST- 2018/08/11 06:00 [entrez]
PHST- 2018/08/11 06:00 [pubmed]
PHST- 2019/02/12 06:00 [medline]
AID - 10.2500/aap.2018.39.4146 [doi]
PST - ppublish
SO  - Allergy Asthma Proc. 2018 Jul 1;39(4):289-291. doi: 10.2500/aap.2018.39.4146.